The VICTORIA trial established that vericiguat, in comparison to placebo, significantly reduced the risk of heart failure hospitalization or cardiovascular death in patients with worsening heart failure with reduced ejection fraction (HFrEF). This study, published in ESC Heart Failure, assessed how vericiguat performed in a group of VICTORIA trial participants with baseline characteristics similar to those in the PARADIGM-HF and DAPA-HF trials. […]
Heart failure with preserved ejection fraction (HFpEF) is a complex condition that often develops in people with multiple other health problems, and is believed to arise from a network of related systemic processes. While existing protein biomarkers for HFpEF exhibit diagnostic limitations, a comprehensive protein analysis approach, known as proteomics, has the potential to improve […]
Alirocumab is an injectable PCSK9 inhibitor that reduces the level of low-density lipoprotein cholesterol (LDL-C), commonly known as “bad” cholesterol. The ODYSSEY OUTCOMES trial demonstrated that, among patients with a recent acute coronary syndrome (ACS) receiving high-intensity statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events and lowered all-cause mortality. Using ODYSSEY OUTCOMES […]
We are pleased to share the 2024 Canadian VIGOUR Centre (CVC) Annual Report, “Research in Motion“. Just as a Rube Goldberg machine transforms a simple action into a complex and interconnected chain reaction, research is a dynamic interplay of innovation, collaboration, and discovery. The CVC is committed to advancing cardiovascular research, recognizing that each step in the process drives […]
CSL112, a plasma-derived apolipoprotein A1, is a component of high-density lipoprotein cholesterol (HDL-C), also known as “good cholesterol”. CSL112 removes plaque from the arteries, and helps facilitate the removal process of low-density lipoprotein cholesterol (LDL-C), the “bad cholesterol”, from the body. The AEGIS-II trial found that CSL112 did not significantly reduce recurrent cardiovascular events compared […]
Cardiogenic shock (CS) is a life-threatening condition that occurs when the heart cannot pump enough blood and oxygen to the brain and other critical organs. While all CS patients experience low cardiac output and resulting end-organ hypoperfusion, data from registries and clinical trials reveal considerable variation in severity, underlying causes, volume status, and systemic vascular […]
Clinical trials in acute care settings, particularly those involving small populations or high mortality rates, face unique challenges in design and analysis. Co-authored by Drs. Fernando Zampieri and Justin Ezekowitz (University of Alberta), this review highlights innovative statistical methods and strategies to address these challenges, with an emphasis on cardiovascular therapies. The authors aim to guide researchers […]
Research from the STREAM-1 and STREAM-2 trials highlights the benefits of using half-dose tenecteplase, a clot-busting drug used to prevent death, for treating elderly patients (aged ≥75 years) with ST-segment elevation myocardial infarction (STEMI). STREAM-1 found that full-dose tenecteplase increased the risk of intracranial hemorrhage in this age group, while halving the dose eliminated this risk. STREAM-2 confirmed that […]
Heart failure (HF) continues to be a significant global health challenge, contributing to high rates of morbidity, mortality, and healthcare costs. Patients who seek care in the emergency department (ED) or are hospitalized for HF face a greater risk of future adverse events, but accurately assessing and categorizing their risk level remains a complex task. […]
Heart failure is common in patients with kidney failure undergoing dialysis, but it is often difficult to distinguish from other conditions with similar symptoms, such as volume overload. For this reason, it is critically important to have standardized diagnostic criteria in randomized clinical trials (RCTs) in order to accurately assess treatment effects. In a recent […]
ST-elevation myocardial infarction (STEMI) occurs when a coronary artery is completely blocked and is the most severe type of heart attack. The STREAM-2 study evaluated the safety of a pharmacoinvasive treatment with half-dose tenecteplase, a clot-busting drug used to prevent death, in STEMI patients aged 60 and older who presented within 3 hours of symptom onset, and […]
Pulmonary arterial hypertension (PAH) is a condition characterized by high blood pressure in the pulmonary artery that carries blood from the heart to the lungs. Clinical trials have led to a growing number of treatment options that can improve symptoms and clinical outcomes for patients with PAH. In a recent international task force summary paper […]
On September 20, 2024, the CVC was pleased to host the 11th annual CVC Colloquium in Edmonton, Alberta. The theme for this year’s meeting was “Shared Best Practices in Clinical Research”. The session opened with a keynote address by Dr. Schuyler Jones (Duke Clinical Research Institute), who shared approaches to partnering with patients in clinical trials and recommended […]
The Healthy Pregnancy Hub is a new canada-wide online platform that provides evidence-based information about the safety of prescription medications during pregnancy. The site launched on November 19th and is based on research from the Canadian Mother-Child Cohort (CAMCCO) collaboration. Although almost 70% of pregnant women take medication, there is limited information available on impact and safety for this […]
Patients with heart failure are often recommended to restrict sodium intake in their diet, however, current scientific evidence does not support limiting dietary sodium to improve clinical outcomes. In this secondary analysis of the SODIUM-HF trial, published in the Journal of Cardiac Failure, researchers investigated the link between baseline dietary sodium intake and change at 6 months, with […]
Pulmonary hypertension (PH) occurs when blood pressure is abnormally high in the lungs. In a state-of-the-art review published in the European Respiratory Journal, led by CVC faculty member Dr. Jason Weatherald, researchers provide a comprehensive overview of the process of determining PH phenotypes (observable traits that result from both genetic and environmental factors), discuss the progress made […]
The VICTORIA study evaluated the efficacy of vericiguat in heart failure patients with reduced ejection fraction, and found that vericiguat reduced the risk of the primary outcome of heart failure hospitalization (HFH) or cardiovascular death (CVD) when compared to placebo. In a recent secondary analysis published in the Journal of Cardiac Failure, researchers applied two alternative methods, the […]
Reverse ventricular remodelling – characterized by a reduction of left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase of left ventricular ejection fraction (LVEF) – is associated with better clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Little is known about the central pathophysiological mechanisms associated with […]
Alirocumab is an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) that reduces the level of low-density lipoprotein-cholesterol and other atherogenic lipoproteins. The ODYSSEY OUTCOMES trial demonstrated that in patients with a recent acute coronary syndrome who were receiving high-intensity statins, alirocumab reduced the risk of recurrent ischemic cardiovascular events and lowered the rate of […]
CSL112 is an apolipoprotein A1 (apoA-I) derived from human plasma, and is a component of high-density lipoprotein (known as the “good” cholesterol). CSL112 removes plaque from the arteries, and helps facilitate cholesterol efflux, the removal process of low-density lipoprotein (known as the “bad” cholesterol) from the body. The AEGIS-II trial determined that CSL112, when compared to placebo, […]
